{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:41:46Z","timestamp":1790743306201,"version":"4.1.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cinacalcet is a calcimimetic approved in adults with primary hyperparathyroidism (PHPT). Few cases reports described its use in pediatric HPT, with challenges related to the risk of hypocalcemia, increased QT interval and drug interactions. In this study, we report the French experience in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed data from 18 pediatric patients from 7 tertiary centers who received cinacalcet for PHPT. The results are presented as median (interquartile range).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At a median age of 10.8 (2.0\u201314.4) years, 18 patients received cinacalcet for primary HPT (\n                      <jats:italic>N<\/jats:italic>\n                      = 13 inactive\n                      <jats:italic>CASR<\/jats:italic>\n                      mutation,\n                      <jats:italic>N<\/jats:italic>\n                      = 1\n                      <jats:italic>CDC73<\/jats:italic>\n                      mutation,\n                      <jats:italic>N<\/jats:italic>\n                      = 1 multiple endocrine neoplasia type 1, N=3 unknown etiology). Cinacalcet was introduced at an estimated glomerular filtration rate (eGFR) of 120 (111\u2013130) mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , plasma calcium of 3.04 (2.96\u20133.14) mmol\/L, plasma phosphate of 1.1 (1.0\u20131.3) mmol\/L, age-standardized (z score) phosphate of \u22123.0 (\u22123.5;\u22121.9), total ALP of 212 (164\u2013245) UI\/L, 25-OHD of 37 (20\u201346) ng\/L, age-standardized (z score) ALP of \u22122.4 (\u22123.7;\u22121.4), PTH of 75 (59\u2013123) ng\/L corresponding to 1.2 (1.0\u20132.3)-time the upper limit for normal (ULN). The starting daily dose of cinacalcet was 0.7 (0.6\u20131.0) mg\/kg, with a maximum dose of 1.0 (0.9\u20131.4) mg\/kg per day. With a follow-up of 2.2 (1.3\u20134.3) years on cinacalcet therapy, PTH and calcium significantly decreased to 37 (34\u201354) ng\/L, corresponding to 0.8 (0.5\u20130.8) ULN (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.01), and 2.66 (2.55\u20132.90) mmol\/L (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002), respectively. In contrast, eGFR, 25-OHD, ALP and phosphate and urinary calcium levels remained stable. Nephrocalcinosis was not reported but one patient displayed nephrolithiasis. Cinacalcet was progressively withdrawn in three patients; no side effects were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cinacalcet in pediatric HPT can control hypercalcemia and PTH without significant side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2022.926986","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T03:57:21Z","timestamp":1661313441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience"],"prefix":"10.3389","volume":"10","author":[{"given":"Julie","family":"Bernardor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Flammier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Amouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Castanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lienhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Martinerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Damgov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1542\/peds.2004-0804","article-title":"Primary hyperparathyroidism in pediatric patients","volume":"115","author":"Kollars","year":"2005","journal-title":"Pediatrics."},{"key":"B2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jcma.2012.06.012","article-title":"Primary hyperparathyroidism in children and adolescents","volume":"75","author":"Roizen","year":"2012","journal-title":"J Chin Med Assoc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1038\/nrdp.2016.33","article-title":"Primary hyperparathyroidism","volume":"2","author":"Bilezikian","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41574-021-00468-3","article-title":"Clinical aspects of multiple endocrine neoplasia type 1","volume":"17","author":"Al-Salameh","year":"2021","journal-title":"Nat Rev Endocrinol."},{"key":"B5","first-page":"1224","article-title":"Groupe d'etude des tumeurs \u00e0 calcitonine. [Polyadenomatoses: type 2 multiple endocrine neoplasms]","volume":"31","author":"Conte-Devolx","year":"2002","journal-title":"Presse Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijporl.2012.12.008","article-title":"Characterization of hyperparathyroidism in youth and adolescents: a literature review","volume":"77","author":"Belcher","year":"2013","journal-title":"Int J Pediatr Otorhinolaryngol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/jcm10081604","article-title":"Primary hyperparathyroidism: a narrative review of diagnosis and medical management","volume":"10","author":"Dandurand","year":"2021","journal-title":"J Clin Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1210\/jc.2014-2000","article-title":"The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop","volume":"99","author":"Udelsman","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000381622","article-title":"Aetiology, diagnosis and surgical treatment of primary hyperparathyroidism in children: new trends","volume":"83","author":"Alagaratnam","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1210\/jcem.85.11.6994","article-title":"Hormonal determinants and disorders of peak bone mass in children1","volume":"85","author":"Soyka","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1345\/aph.1D108","article-title":"Calcimimetics and the treatment of primary and secondary hyperparathyroidism","volume":"38","author":"Joy","year":"2004","journal-title":"Ann Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1530\/EC-20-0221","article-title":"Cinacalcet and primary hyperparathyroidism: systematic review and meta regression","volume":"9","author":"Ng","year":"2020","journal-title":"Endocr Connect."},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/ndt\/gfz159","article-title":"Cinacalcet in pediatric dialysis: a position statement from the ESPN and the CKD-MBD working groupe of the ERA-EDTA","volume":"35","author":"Bacchetta","year":"2020","journal-title":"Nephrol Dial Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5539349","DOI":"10.1155\/2021\/5539349","article-title":"Primary Hyperparathyroidism (PHPT) in children: two case reports and review of the literature","volume":"2021","author":"Tuli","year":"2021","journal-title":"Case Rep Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e13128","DOI":"10.1097\/MD.0000000000013128","article-title":"Novel homozygous inactivating mutation of the calcium-sensing receptor gene in neonatal severe hyperparathyroidism responding to cinacalcet therapy","volume":"97","author":"Sun","year":"2018","journal-title":"Medicine."},{"key":"B17","first-page":"584","article-title":"Evaluation of bone and mineral disorders","volume":"5","author":"Ardeshirpour","year":"2007","journal-title":"Pediatr Endocrinol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0022-3476(97)70162-8","article-title":"Urinary phosphate\/creatinine, calcium\/creatinine, and magnesium\/creatinine ratios in a healthy pediatric population","volume":"131","author":"Matos","year":"1997","journal-title":"J Pediatr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4274\/jcrpe.v3i1.02","article-title":"Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets","volume":"3","author":"Turan","year":"2011","journal-title":"J Clin Res Pediatr Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1373\/clinchem.2006.070219","article-title":"Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl","volume":"52","author":"Henrich","year":"2006","journal-title":"Clin Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00467-010-1547-5","article-title":"Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia","volume":"25","author":"Alon","year":"2010","journal-title":"Pediatr Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"E707o12","DOI":"10.1210\/jc.2010-1306","article-title":"Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet","volume":"96","author":"Reh","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e812","DOI":"10.1542\/peds.2011-0128","article-title":"Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism","volume":"129","author":"Wilhelm-Bals","year":"2012","journal-title":"Pediatrics."},{"key":"B25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000350540","article-title":"Neonatal hypercalcemia due to a homozygous mutation in the calcium-sensing receptor: failure of cinacalcet","volume":"104","author":"Garc\u00eda Soblechero","year":"2013","journal-title":"Neonatology."},{"key":"B26","first-page":"102t","article-title":"Novel homozygous inactivating mutation of the calcium-sensing receptor gene (CASR) in neonatal severe hyperparathyroidism-lack of effect of cinacalcet","volume-title":"Bone.","author":"Atay","year":"2014"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1210\/jc.2013-2834","article-title":"Cinacalcet monotherapy in neonatal severe hyperparathyroidism: a case study and review","volume":"99","author":"Gannon","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1210\/jc.2015-1518","article-title":"M\u00e4kitie O. Cinacalcet treatment in an adolescent with concurrent 22q112 deletion syndrome and familial hypocalciuric hypercalcemia type 3 caused by AP2S1 mutation","volume":"100","author":"Tenhola","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"150040","DOI":"10.1530\/EDM-15-0040","article-title":"Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients","volume":"2015","author":"Fisher","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00467-015-3271-7","article-title":"Cinacalcet as adjunctive therapy in pseudohypoparathyroidism type 1b","volume":"31","author":"Srivastava","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1515\/jpem-2015-0261","article-title":"Treatment experience and long-term follow-up data in two severe neonatal hyperparathyroidism cases","volume":"29","author":"Savas-Erdeve","year":"2016","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejmg.2016.02.001","article-title":"Neonatal severe hyperparathyroidism caused by homozygous mutation in CASR: a rare cause of life-threatening hypercalcemia","volume":"59","author":"Murphy","year":"2016","journal-title":"Eur J Med Genet."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13346","article-title":"Cinacalcet as an alternative to phosphate therapy in X-linked hypophosphataemic rickets","volume":"114","author":"Alon","year":"2017","journal-title":"Clin Endocrinol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.11138\/ccmbm\/2017.14.3.354","article-title":"Neonatal severe hyperparathyroidism secondary to a novel homozygous CASR gene mutation","volume":"14","author":"Ahmad","year":"2017","journal-title":"Clin Cases Miner Bone Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"EDM180009","DOI":"10.1530\/EDM-18-0009","article-title":"Successful use of cinacalcet to treat parathyroid-related hypercalcemia in two pediatric patients","volume":"2018","author":"Mogas","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12887-018-1319-0","article-title":"Case report: acute clinical presentation and neonatal management of primary hyperparathyroidism due to a novel CaSR mutation","volume":"18","author":"Capozza","year":"2018","journal-title":"BMC Pediatr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.pan.2019.07.045","article-title":"Cinacalcet sustainedly prevents pancreatitis in a child with a compound heterozygous SPINK1\/AP2S1 mutation","volume":"19","author":"Scheers","year":"2019","journal-title":"Pancreatology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4038\/cmj.v64i4.8988","article-title":"Neonatal severe hyperparathyroidism due to a homozygous mutation of calcium-sensing receptor; a challenging case","volume":"64","author":"Hashim","year":"2019","journal-title":"Ceylon Med J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1515\/jpem-2018-0307","article-title":"Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature","volume":"32","author":"Forman","year":"2019","journal-title":"J Pediatr Endocrinol Metabol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/ijem.IJEM_53_20","article-title":"Neonatal severe primary hyperparathyroidism: a series of four cases and their long-term management in India","volume":"24","author":"Sadacharan","year":"2020","journal-title":"Indian J Endocrinol Metab."},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1159\/000510623","article-title":"Cinacalcet as a first-line treatment in neonatal severe hyperparathyroidism secondary to calcium sensing receptor (CaSR) mutation","volume-title":"Horm Res Paediatr.","author":"Gulcan-Kersin","year":"2020"},{"key":"B42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijscr.2019.12.024","article-title":"A rare cause of neonatal hypercalcemia: Neonatal severe primary hyperparathyroidism: a case report and review of the literature","volume":"66","author":"Abdullayev","year":"2020","journal-title":"Int J Surg Case Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.bonr.2021.100761","article-title":"novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug","volume":"14","author":"Leunbach","year":"2021","journal-title":"Bone Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.bonr.2021.101097","article-title":"Prenatal features and neonatal management of severe hyperparathyroidism caused by the heterozygous inactivating calcium-sensing receptor variant, Arg185Gln: a case report and review of the literature","volume":"15","author":"Aubert-Mucca","year":"2021","journal-title":"Bone Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.31729\/jnma.6411","article-title":"Hereditary vitamin-D dependent rickets type II: a case report","volume":"59","author":"Sunuwar","year":"2021","journal-title":"JNMA J Nepal Med Assoc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1515\/JPEM.2009.22.6.561","article-title":"Neonatal hypercalcemia due to polymorphisms of the calcium sensing receptor","volume":"22","author":"Jack","year":"2009","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B47","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/ijms19040999","article-title":"The different facets of extracellular calcium sensors: old and new concepts in calcium-sensing receptor signalling and pharmacology","volume":"19","author":"Gerbino","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5152\/AnatolJCardiol.2015.6284","article-title":"Effects of cinacalcet treatment on QT interval in hemodialysis patients","volume":"16","author":"Temiz","year":"2016","journal-title":"Anatol J Cardiol."},{"key":"B49","first-page":"8","article-title":"Calcium sensing receptor and renal mineral ion transport","volume":"34","author":"Rainone","year":"2011","journal-title":"J Endocrinol Invest."},{"key":"B50","doi-asserted-by":"publisher","first-page":"F1233","DOI":"10.1152\/ajprenal.00249.2003","article-title":"Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport","volume":"285","author":"Ba","year":"2003","journal-title":"Am J Physiol Renal Physiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/emboj.2012.49","article-title":"Claudin-14 regulates renal Ca++ transport in response to CaSR signalling via a novel microRNA pathway","volume":"31","author":"Gong","year":"2012","journal-title":"EMBO J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1172\/JCI119299","article-title":"Apical extracellular calcium\/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct","volume":"99","author":"Sands","year":"1997","journal-title":"J Clin Invest."},{"key":"B53","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1124\/pr.119.018531","article-title":"International union of basic and clinical pharmacology. CVIII. Calcium-sensing receptor nomenclature, pharmacology, and function","volume":"72","author":"Leach","year":"2020","journal-title":"Pharmacol Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1210\/jc.2008-1076","article-title":"Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors","volume":"93","author":"Rus","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B55","first-page":"775","article-title":"Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor","volume-title":"J Pharmacol Exp Ther.","author":"Lu","year":"2009"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.926986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T03:57:31Z","timestamp":1661313451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.926986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":55,"alternative-id":["10.3389\/fped.2022.926986"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.926986","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"article-number":"926986"}}